Status:
COMPLETED
A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Influenza
Eligibility:
All Genders
18-35 years
Phase:
PHASE1
Brief Summary
This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and IMX, a saponin-based ad...
Eligibility Criteria
Inclusion
- Subject is in good physical health
- Subject is not in the category of individuals recommended by the CDC to receive influenza vaccine for the upcoming 2 influenza seasons
- Subject agrees not to seek vaccination with licensed influenza vaccines during the study
- Female subjects agree to use acceptable birth control for 6 weeks prior to first dose of vaccine until 1 month post Dose 3
Exclusion
- Subject has a history of allergic reaction to the vaccine components
- Subject has has a fever within 3 days of screening
- Subject had a vaccination with an inactive virus within 14 days of Dose 1
- Subject had a vaccination with a live virus within 30 days of Dose 1
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT00851266
Start Date
October 1 2006
End Date
January 1 2009
Last Update
February 12 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.